To verify whether YY1 can be degraded through ubiquitin–proteasome pathway in breast cancer cells, MDA-MB-231, Hs578T, and MCF-7 cells were treated with proteosome inhibitor MG-132 for the indicated times. Here, YY1 is linked to breast carcinoma.